Barchart on Facebook
Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.

Stocks | Futures | Watchlist | More
or

Mylan NV Ord Shs (MYL)

Mylan NV Ord Shs (MYL)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 7,826,578
  • Shares Outstanding, K 516,947
  • Annual Sales, $ 11,501 M
  • Annual Income, $ 16,800 K
  • 60-Month Beta 1.46
  • Price/Sales 0.69
  • Price/Cash Flow 1.84
  • Price/Book 0.67
Trade MYL with:

Analyst Rating / Earnings Estimates

Current Rating
See More
Moderate Buy
Based on 11 analysts offering recommendations.
Earnings Estimates - Current Qtr 09/30/20
See More
  • Average Estimate 1.15
  • Number of Estimates 7
  • High Estimate 1.21
  • Low Estimate 1.10
  • Prior Year 1.17
  • Growth Rate Est. (year over year) -1.71%

Price Performance

See More
Period Period Low Period High Performance
1-Month
14.02 +11.27%
on 09/24/20
16.08 -2.99%
on 10/16/20
+0.78 (+5.26%)
since 09/22/20
3-Month
14.02 +11.27%
on 09/24/20
17.69 -11.81%
on 08/06/20
-0.97 (-5.85%)
since 07/22/20
52-Week
12.75 +22.35%
on 03/16/20
23.11 -32.50%
on 02/06/20
-2.71 (-14.80%)
since 10/22/19

Most Recent Stories

More News
Biogen (BIIB) Q3 Earnings Top, Tecfidera Generics Hurt Sales

Biogen (BIIB) beats third-quarter estimates for both earnings and sales. Tecfidera generics hurts sales, resulting in guidance cut.

BIIB : 266.80 (-0.78%)
JNJ : 145.08 (+0.80%)
RHHBY : 40.9500 (-0.32%)
MYL : 15.60 (+3.04%)
Mapi Pharma Announces Commissioning of a Vaccine Production Facility to Support the Supply of COVID-19 Vaccines to Israel and EU Countries

Mapi Pharma Ltd., a fully integrated, late clinical stage biopharmaceutical company, today announced that it will dedicate capacity at its manufacturing facility to support the global effort to provide...

MAPI : N/A (unch)
MYL : 15.60 (+3.04%)
Watch for Shares of Mylan Nv (MYL) to Approach Resistance at $15.16

Shares of Mylan Nv (NASDAQ:MYL) opened today above their pivot of $14.82 and have already reached the first level of resistance at $15.00. Analysts will be watching for a cross of the next upside pivot...

MYL : 15.60 (+3.04%)
Downtrend Call Working As Mylan Nv Stock Falls 9.5% (MYL)

SmarTrend identified a Downtrend for Mylan Nv (NASDAQ:MYL) on June 15th, 2020 at $15.71. In approximately 3 months, Mylan Nv has returned 9.52% as of today's recent price of $14.21.

MYL : 15.60 (+3.04%)
Roche Buys NLRP3 Inflammasome Inhibitors Developer Inflazome

Roche (RHHBY) buys Inflazome for ???euro 380 million and gains access to pipeline of small molecule NLRP3 inhibitors.

RHHBY : 40.9500 (-0.32%)
PFE : 37.43 (+0.94%)
MYL : 15.60 (+3.04%)
SRPT : 137.80 (+0.39%)
Mylan/Pfizer's Upjohn Unit Merger on Track to Close in Q4

The pending merger of Pfizer's (PFE) Upjohn unit with Mylan (MYL) is on track to close in the fourth quarter of 2020 as almost all necessary regulatory clearances are in place.

PFE : 37.43 (+0.94%)
GILD : 60.67 (+0.76%)
MYL : 15.60 (+3.04%)
GSK : 35.09 (-0.74%)
Mylan and Development Partner, Synthon, Win Significant European Patent Office Ruling Related to Copaxone® 40mg/mL

and , /PRNewswire/ -- Mylan N.V. (NASDAQ: MYL) today announced that the Technical Board of Appeal of the European Patent Office (EPO) has held that Yeda Research and Development Company, Ltd.'s European...

MYL : 15.60 (+3.04%)
Mylan and Pfizer Receive European Commission Approval for Proposed Combination of Mylan and Upjohn

, and , /PRNewswire/ -- Mylan  (NASDAQ: MYL) and Pfizer Inc. (NYSE: PFE) today announced that the companies have received final approval from the European Commission (EC) for the proposed combination...

MYL : 15.60 (+3.04%)
PFE : 37.43 (+0.94%)
Mapi Pharma Presents Glatiramer Acetate Depot (GA Depot) Results at the 8th Joint ACTRIMS-ECTRIMS Meeting MSVirtual2020

90% of relapsing remitting multiple sclerosis (RRMS) patients on GA Depot demonstrated no evidence of disease activity (NEDA) at four years

MAPI : N/A (unch)
MYL : 15.60 (+3.04%)
Mylan to Buy Aspen Pharmacare's Thrombosis Business in Europe

Mylan (MYL) will acquire Aspen Pharmacare's thrombosis business in Europe and expand its complex injectables offering and presence in hospitals.

PFE : 37.43 (+0.94%)
MYL : 15.60 (+3.04%)
GSK : 35.09 (-0.74%)
TBPH : 19.03 (+5.31%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 64% Sell with a Weakest short term outlook on maintaining the current direction.

Long term indicators fully support a continuation of the trend.

See More Share

Business Summary

Mylan NV is a pharmaceutical company. The company develops, licenses, manufactures, markets and distributes generic and specialty pharmaceuticals. It operates primarily in the United States, Canada, Europe, the Middle East, Africa, India, Australia, Japan and New Zealand. Mylan NV, formerly known as...

See More

Key Turning Points

2nd Resistance Point 16.12
1st Resistance Point 15.86
Last Price 15.60
1st Support Level 15.21
2nd Support Level 14.82

See More

52-Week High 23.11
Fibonacci 61.8% 19.15
Fibonacci 50% 17.93
Fibonacci 38.2% 16.71
Last Price 15.60
52-Week Low 12.75

See More

Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.
Get Streaming Chart Updates
Switch your Site Preferences
to Interactive Chart
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar